您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Dacarbazine(DTIC)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Dacarbazine(DTIC)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Dacarbazine(DTIC)图片
CAS NO:4342-03-4
规格:≥98%
包装与价格:
包装价格(元)
250mg电议
500mg电议
1g电议
2g电议
5g电议
10g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)182.18
FormulaC6H10N6O
CAS No.4342-03-4
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 3 mg/mL (16.5 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)0.5% CMC Na: 30mg/mL
SynonymsDTIC-Dome; WR139007; Biocarbazine; Dacarbazine; DTIC; Dakarbazin; WR 139007; WR-139007; US trade name: DTICDome. Foreign trade names: Asercit; Dacatic; Deticene; Detimedac; Fauldetic.
实验参考方法
In Vitro

In vitro activity: Treatment of Dacarbazine sensitizes melanomas to lysis of peptide-specific CTL and it is is mediated through Fas-independent pathway.


Cell Assay: Apotosis assay: UACC903 (UACC) cells treated with or without DTIC (20 μM) for 48 h are incubated with agonist anti-Fas Ab, CH-11 (500 ng/ml), for 5 and 16 h, respectively. To distinguish whether death/apoptosis is mediated by FasR, blocking anti-Fas Ab ZB4 (2 mg/ml) is added in the corresponding groups. At the end of incubation, cells are harvested and stained with propidium iodide and FITC-annexin V (BD PharMingen) for detecting apoptosis according to the instruction provided by the company. Ten thousand cells from each group are collected, and dead and apoptotic cells are analyzed without gating using CellQuest software.

In VivoTreatment of combination of Axitinib and DTIC demonstrates significant antitumor activity against melanoma flank xenografts, reduces tumor cell proliferation and decreases the area of tumor necrosis and increases apoptosis. It also reduces meta-tasis-related factors and prolongs lifespan in mice
Animal modelB16F1 melanoma xenograft model(C57BL/6 mice background)
Formulation & DosageDissolved in 0.9% sodium chloride; 80 mg/kg; i.p. injection
ReferencesJ Exp Clin Cancer Res. 2000 Mar;19(1):21-34; J Immunol. 2004 Apr 1;172(7):4599-608; Oncol Lett. 2013 Jul;6(1):69-74.